ImmunityBio, Inc. vs Celldex Therapeutics, Inc.: SG&A Expense Trends

SG&A Expense Trends: ImmunityBio, Inc. vs Celldex Therapeutics, Inc.

In the ever-evolving biotech industry, understanding financial trends is crucial for investors and stakeholders. Over the past decade, ImmunityBio, Inc. and Celldex Therapeutics, Inc. have shown distinct trajectories in their Selling, General, and Administrative (SG&A) expenses. ImmunityBio's SG&A expenses surged by over 2,900% from 2014 to 2023, reflecting its aggressive expansion and operational scaling. In contrast, Celldex Therapeutics experienced a more modest increase of approximately 50% during the same period, indicating a more stable growth strategy.

The year 2015 marked a significant leap for ImmunityBio, with expenses peaking at over 2.26 times their 2014 figures, while Celldex's expenses peaked in 2016. These trends highlight the contrasting business strategies of these biotech firms, offering valuable insights into their operational priorities and market positioning.